Article
Pharmacology & Pharmacy
Silong Chen, Chengshou Zhang, Lifang Shen, Jianghua Hu, Xiangjun Chen, Yibo Yu
Summary: This review summarizes the research on the role of non-coding RNA (ncRNA) in cataracts. Recent studies have found that ncRNA plays a significant role in cataract formation by regulating cellular activities. Due to its importance in cataracts, further research on novel regulatory mechanisms is urgently needed, and the development of alternative therapies for cataract treatment seems promising.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Multidisciplinary Sciences
Yuriki Sakurai, Kyungmin Baeg, Andy Y. W. Lam, Keisuke Shoji, Yukihide Tomari, Hiro-oki Iwakawa
Summary: This study uncovers the molecular mechanisms underlying the production of secondary siRNAs in plants, and highlights the impact of the integrity of different small RNA binding sites on RDR6.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Oncology
Ji Young Yoo, Margaret Yeh, Balveen Kaur, Tae Jin Lee
Summary: Aberrant gene and miRNA expression can drive cancer development, and the modulation of these expressions provides a therapeutic opportunity. Recent advances in RNA nanotechnology offer potential for miRNA therapy, but the lack of a delivery platform remains a challenge.
Review
Oncology
Marco De Martino, Francesco Esposito, Maria Capone, Pierlorenzo Pallante, Alfredo Fusco
Summary: Thyroid tumors are the most common neoplastic pathology of the endocrine system, with mutations in oncogenes and tumor suppressor genes playing a role in their development. Noncoding RNAs have been found to be crucial in regulating gene expression and tumor progression in thyroid cancer. Evaluating the noncoding RNA network could lead to a more personalized approach in the diagnosis, prognosis, and treatment of thyroid cancer.
Review
Cell & Tissue Engineering
Lukasz Pulik, Bartosz Mierzejewski, Aleksandra Sibilska, Iwona Grabowska, Maria Anna Ciemerych, Pawel Legosz, Edyta Brzoska
Summary: Heterotopic ossification is the formation of bone in non-osseous tissues, and it can be caused by genetic or non-genetic factors. TGF beta 1, BMPs, activin A, and other factors are known to induce HO. Dysregulation of noncoding RNAs may also play a role in the development of HO.
STEM CELL RESEARCH & THERAPY
(2022)
Review
Biochemistry & Molecular Biology
Seung Wan Son, Mun Gyu Song, Ba Da Yun, Jong Kook Park
Summary: Therapeutic resistance is a major obstacle in cancer treatment, regulated by signaling pathways and noncoding RNAs.
Review
Cell Biology
Alessio Grimaldi, Giuseppe Pietropaolo, Helena Stabile, Andrea Kosta, Cristina Capuano, Angela Gismondi, Angela Santoni, Giuseppe Sciume, Cinzia Fionda
Summary: Innate lymphoid cells (ILCs) are innate lymphocytes that play essential roles in host protection and pathological conditions. Besides lineage-defining transcription factors, ncRNAs also play crucial roles in controlling ILC development and function, mainly by regulating gene expression to tune distinct functional outputs in ILCs.
Review
Neurosciences
Ying Bai, Hui Ren, Liang Bian, You Zhou, Xinping Wang, Zhongli Xiong, Ziqi Liu, Bing Han, Honghong Yao
Summary: Non-coding RNAs, such as microRNAs, long ncRNAs, and circular RNAs, are highly expressed in the brain and play critical roles in regulating the physiological and pathological processes of central nervous system diseases. Elucidating the mechanisms of ncRNAs in regulating glial function could lead to the identification of novel therapeutic targets for CNS diseases.
NEUROSCIENCE BULLETIN
(2023)
Article
Cell Biology
Livia Fratini, Mariane Jaeger, Caroline Brunetto de Farias, Andre T. Brunetto, Algemir L. Brunetto, Lisa Shaw, Rafael Roesler
Summary: The transcription factor ZEB1 plays a critical role in cell function and embryonic development, with its activities regulated by interactions with miRNAs and lncRNAs. While the exact role of ZEB1 in pediatric cancer is still unclear, emerging evidence suggests its involvement in regulating solid tumors in children.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2021)
Review
Oncology
Maria Teresa Di Martino, Caterina Riillo, Francesca Scionti, Katia Grillone, Nicoletta Polera, Daniele Caracciolo, Mariamena Arbitrio, Pierosandro Tagliaferri, Pierfrancesco Tassone
Summary: Cancer onset and progression are influenced by immune system dysregulation, with noncoding RNAs playing a role in cancer cell immune escape and modulation of the tumor microenvironment. While immunotherapy holds promise for cancer treatment, efforts are needed to achieve cure for immune-refractory tumors.
Review
Biochemistry & Molecular Biology
Sumio Hayakawa, Tomokazu Ohishi, Yumiko Oishi, Mamoru Isemura, Noriyuki Miyoshi
Summary: Polyphenols have anticancer effects by acting as antioxidants and modulating cell signaling pathways, with ncRNA modulation enhancing these effects.
Review
Pharmacology & Pharmacy
Hyunjong Kim, Jaesub Kim, Juhee Ryu
Summary: Retinopathy of prematurity (ROP) is a vascular disease that has become a primary cause of blindness in children worldwide. Although current therapies such as laser therapy and pharmacologic agents are commonly used to treat ROP, the search for novel therapeutic targets with less destructive properties is necessary. Noncoding RNA therapy has shown potential as next-generation therapy for treating ROP by regulating various noncoding RNAs.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Amir Safi, Mohammadreza Saberiyan, Mohammad-Javad Sanaei, Samaneh Adelian, Fateme Davarani Asl, Mahsa Zeinaly, Mahdi Shamsi, Reza Ahmadi
Summary: Metabolic reprogramming is a well-known feature of cancer, and noncoding RNAs (ncRNAs) have been found to play a role in this process. This review focuses on the metabolism of glucose, lipids, and amino acids in cancer cells, and highlights the therapeutic potential of targeting ncRNAs in cancer treatment.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2023)
Review
Pharmacology & Pharmacy
Chenggui Miao, Wanwan Zhou, Xiao Wang, Jihong Fang
Summary: Exosomes play important roles in the pathogenesis of osteoarthritis by regulating cell communication and biological activity through carrying RNA and proteins. Therefore, exploring the roles of exosomes in osteoarthritis can help to better understand the disease mechanism and discover new diagnostic biomarkers and therapeutic targets.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Zhengjun Lin, Xubin Xie, Shiyao Lu, Tang Liu
Summary: Osteosarcoma is the most frequent bone malignancy in children and adolescents, with the development of multi-drug resistance posing a major obstacle in improving chemotherapy efficacy. Research has shown that noncoding RNAs play significant roles in osteosarcoma progression and chemosensitivity, highlighting their potential as biomarkers and therapeutic targets for improving patient prognosis.
Article
Oncology
Maxine Umeh-Garcia, Catalina Simion, Pui-Yan Ho, Neelu Batra, Anastasia L. Berg, Kermit L. Carraway, Aiming Yu, Colleen Sweeney
Review
Pharmacology & Pharmacy
Ai-Ming Yu, Young Hee Choi, Mei-Juan Tu
PHARMACOLOGICAL REVIEWS
(2020)
Article
Pharmacology & Pharmacy
Hannah Petrek, Pui Yan Ho, Neelu Batra, Mei-Juan Tu, Qianyu Zhang, Jing-Xin Qiu, Ai-Ming Yu
Summary: This study introduces a novel technology for dual-targeting of two miRNAs in NSCLC cells, showing greater efficacy in inhibiting cell growth and colony formation compared to using individual miRNAs alone. Additionally, a specific miRNA-loaded nanomedicine demonstrated the best effectiveness in controlling tumor growth in NSCLC patient-derived xenograft mouse models.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Young Hee Choi, Chao Zhang, Zhenzhen Liu, Mei-Juan Tu, Ai-Xi Yu, Ai-Ming Yu
Summary: This study developed a novel pharmacokinetic (PK)-pharmacodynamic (PD) model for assessing combination treatment by considering contributions from individual drugs, and incorporated the combination index method to define in vivo synergism accurately. The research found that sorafenib contributed more to tumor growth inhibition compared to coadministered doxorubicin, explaining previously inexplicable clinical observations. This model and strategy will have broad applications in translational research for identifying optimal dosage combinations with stronger synergy to improve therapeutic outcomes.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2021)
Editorial Material
Pharmacology & Pharmacy
Baitang Ning, Ai-Ming Yu
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Xiong Zhang, Zenghong Huang, Junjian Wang, Zhao Ma, Joy Yang, Eva Corey, Christopher P. Evans, Ai-Ming Yu, Hong-Wu Chen
Summary: Prostate cancer is a common cancer in men with limited therapeutic options, but targeting drivers other than AR, such as RORgamma, may provide new treatment strategies. The study demonstrated that RORgamma antagonists effectively inhibit the growth of advanced prostate cancer tumors, suggesting a promising new approach for treating this aggressive disease.
Article
Biochemistry & Molecular Biology
Chengfei Liu, Cameron M. Armstrong, Shu Ning, Joy C. Yang, Wei Lou, Alan P. Lombard, Jinge Zhao, Chun-Yi Wu, Aiming Yu, Christopher P. Evans, Clifford G. Tepper, Pui-kai Li, Allen C. Gao
Summary: The use of a novel AR/AR-V7 degrader ARVib effectively degrades AR/AR-V7 protein in prostate cancer cells and attenuates AR/AR-V7 downstream target gene expression. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation, which inhibits resistant prostate tumor growth and improves enzalutamide treatment both in vitro and in vivo. These findings suggest that ARVib has potential as a therapy for resistant CRPC by targeting AR/AR-V7 degradation.
Article
Pharmacology & Pharmacy
Linglong Deng, Hannah Petrek, Mei-Juan Tu, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu
Summary: This study investigates the molecular and cellular mechanisms of miR-124-3p in controlling tumor metastasis by downregulating proteins critical for metastatic potential. The findings suggest that miR-124-3p therapy could inhibit cancer cell invasion and metastasis by disrupting cell structures and interactions.
ACTA PHARMACEUTICA SINICA B
(2021)
Article
Oncology
Anastasia L. Berg, Ashley Rowson-Hodel, Michelle Hu, Michael Keeling, Hao Wu, Kacey VanderVorst, Jenny J. Chen, Jason Hatakeyama, Joseph Jilek, Courtney A. Dreyer, Madelyn R. Wheeler, Ai-Ming Yu, Yuanpei Li, Kermit L. Carraway
Summary: Preventing drug resistance in cancer stem cells is crucial for improving treatment outcomes in cancer patients. This study found that cationic amphiphilic drugs can effectively target therapy-resistant cancer stem cell populations by inducing cell death through a different mechanism. This discovery has the potential to improve treatment outcomes for breast cancer patients and reduce the risk of tumor recurrence and metastasis.
Review
Pharmacology & Pharmacy
Gavin M. Traber, Ai-Ming Yu
Summary: RNA interference (RNAi) is a versatile method for regulating gene expression. Endogenous microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs) form RNA-induced silencing complexes to achieve gene regulation. RNAi-based drugs have been approved for clinical use and advancements in technology aim to improve their efficacy and safety. Chemical modifications and delivery platforms are being explored to enhance the structure, stability, and activity of RNA molecules. Novel biologic RNAi agents are also being developed for research purposes.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2023)
Article
Oncology
Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Summary: Next-generation antiandrogen drugs improve survival and quality of life in advanced prostate cancer patients, but resistance to these drugs is not well understood. This study found that the Wnt5a/FZD2 signaling pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway could be a potential therapy for advanced prostate cancer.
MOLECULAR CANCER THERAPEUTICS
(2022)
Review
Pharmacology & Pharmacy
Joseph M. Cronin, Ai -Ming Yu
Summary: The development of medications requires a thorough understanding of their pharmacokinetic and pharmacodynamic properties. The study of ADME gene products and their functions has been revolutionized by recombinant DNA technologies. These technologies enable the investigation of drug metabolism and disposition, as well as the study of posttranscriptional regulation of ADME genes.
DRUG METABOLISM AND DISPOSITION
(2023)
Article
Pharmacology & Pharmacy
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong -Wu Chen, Huichang Bi, Ai -Ming Yu
Summary: The research found that miR-22-3p, miR-9-5p, and miR-218-5p are antiproliferative miRNAs targeting non-small cell lung cancer (NSCLC) cells, and they inhibit folate metabolism and alter amino acid metabolism in NSCLC cells. In addition, the inhibition of glucose uptake by miR-22-3p and the reduction of serine biosynthesis from glucose by miR-9-5p and -218-5p were also confirmed. Recombinant miR-22-3p was more effective than miR-9-5p and -218-5p in inhibiting NSCLC cell respiration, glycolysis, and colony formation, without causing any toxicity.
ACTA PHARMACEUTICA SINICA B
(2023)
Article
Medicine, Research & Experimental
Yixin Chen, Yanying Zhou, Fangwei Han, Yingyuan Zhao, Meijuan Tu, Yongtao Wang, Can Huang, Shicheng Fan, Panpan Chen, Xinpeng Yao, Lihuan Guan, Ai -Ming Yu, Frank J. Gonzalez, Min Huang, Huichang Bi
Article
Medicine, Research & Experimental
Peng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, Neelu Batra, Michelle M. L. Tran, Jing-Xin Qiu, Theodore Wun, Primo N. Lara, Xiang Hu, Ai-Xi Yu, Ai-Ming Yu
Summary: A novel platform for in vivo fermentation production of humanized recombinant ncRNA molecules was developed, demonstrating their important roles in cellular processes and anti-tumor activities. The technology represents a unique addition to conventional technologies for basic research and drug development.